Life Sciences 2022 Year in Review
XTalks
DECEMBER 21, 2022
In 2022, the US Food and Drug Administration (FDA) approved the following four new gene therapies: Adstiladrin (nadofaragene firadenovec-vncg) for the treatment of adult patients with high-risk Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
52 
Let's personalize your content